Background and Aims

Glycaemic control in pediatric patients with Type 1 Diabetes (T1D) continues being a challenge. Insulin infusion systems are being developed that optimize and personalize insulin delivery.

The Medtronic MiniMed™780G is a new generation closed-loop hybrid system, that automatically adjusts insulin delivery and corrects glucose levels every five minutes to a modifiable target.

The aim of the study is to analyse glycaemic control data and glycaemic variability in pediatric patients with T1D after change from their usual treatment to the Medtronic™780G advanced close-loop system.

Methods

This is a prospective study in pediatric patients that begin treatment with the closed-loop system Minimed™780G, from different previous treatments. Data on glucose control and glycemic variability were studied at the beginning and 6 months after treatment.

Results

Twenty-eight patients (15 of them women) with a mean age of 13,5 years were studied. Four patients had previous treatment with MiniMed™640G system (sensor augmented pump with predictive low glucose suspend). The rest of the patients were in treatment with multiple daily injections, 19 of them associated continuous glucose monitoring with DEXCOM™G6 and the other 5 associated flash glucose monitoring with FREESTYLE2™.

A statistically significant reduction in HbA1c was observed, as well as an increase in time in range 70-180 mg/dl, a decrease in time in hyperglycemia and a reduction in time of hypoglycemia. An improvement in glycemic variability is also observed.

The results of the study are shown in table 1.

Conclusions

The new MiniMed™780G advanced closed-loop system improves metabolic control in pediatric patients with T1D, regardless of previous treatment.